Presgrave P, Woods R, Dalley D, Bell D, Levi J
Department of Clinical Oncology, Royal North Shore Hospital, St. Leonards, NSW, Australia.
Am J Clin Oncol. 1988 Oct;11(5):564-5. doi: 10.1097/00000421-198810000-00011.
4'Demethoxydaunorubicin (DMDR), an orally active daunorubicin analogue, was administered to 22 patients with advanced colorectal carcinoma. Patients were stratified into good- and poor-risk categories and received doses of 45 mg/m2 and 40 mg/m2, respectively, at 28-day intervals. Twenty-one patients were evaluable for response. No tumour responses occurred, although six patients had stable disease. Therapy was well tolerated. Mild gastrointestinal toxicity occurred in 45% of patients. Marrow toxicity was common and usually mild. DMDR appears to have no useful activity in colorectal carcinoma.
4'-去甲氧基柔红霉素（DMDR）是一种口服活性柔红霉素类似物，应用于22例晚期结直肠癌患者。患者被分为低风险和高风险类别，分别接受45mg/m²和40mg/m²的剂量，每28天给药一次。21例患者可评估疗效。虽有6例患者疾病稳定，但未出现肿瘤反应。治疗耐受性良好。45%的患者出现轻度胃肠道毒性。骨髓毒性常见且通常较轻。DMDR在结直肠癌中似乎没有有效的活性。
